Муцины как фактор канцерогенеза и потенциальная мишень терапии муцинозных опухолей яичников
https://doi.org/10.17650/1994-4098-2024-20-4-127-132
Аннотация
Муцинозная карцинома яичников – редкая гистологическая форма эпителиального рака яичников. Данные опухоли демонстрируют плохой объективный ответ на стандартные схемы химиотерапии для эпителиального рака яичников и поддерживающую терапию ингибиторами PARP, что приводит к короткому периоду общей и безрецидивной выживаемости, а также неблагоприятному прогнозу у пациенток с поздними стадиями заболевания. Макроскопически муцинозная карцинома яичников характеризуется наличием в кистозной полости слизи, состоящей в основном из муцина. В настоящем обзоре подробно рассмотрена роль муцинов в патогенезе и терапии муцинозной карциномы яичников в контексте формирования химиорезистентности и возможной точки приложения для таргетной терапии.
Об авторах
А. Г. Кедрова
ФГБУ «Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий Федерального медико-биологического агентства России»
Россия
Россия
Россия, 115682 Москва, Ореховый бульвар, 28
Т. А. Греян
ФГБУ «Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий Федерального медико-биологического агентства России»
Россия
Россия
Татевик Ахуриковна Греян
Россия, 115682 Москва, Ореховый бульвар, 28
Список литературы
1. Reynolds I.S., Fichtner M., McNamara D.A. et al. Mucin glycoproteins block apoptosis; promote invasion, proliferation, and migration; and cause chemoresistance through diverse pathways in epithelial cancers. Cancer Metastasis Rev 2019;38:237–57. DOI: 10.1007/s10555-019-09781-w
2. Xie L., Liu J., Wang H. The expression of mucin 1 in tumor cells and its research progress as a therapeutic target. Oncology Progress 2022;20(5):449–53. DOI: 10.11877/j.issn.1672-1535.2022.20.05.05.
3. Li Y.R., Lin P. Expression and significance of MUC1 and BDNF in epithelial ovarian cancer. Int J Lab Med 2022;1:110–3. DOI: 10.3969/j.issn.1673-4130.2022.01.023
4. Hou R., Jiang L., Liu D. et al. Lewis(y) antigen promotes the progression of epithelial ovarian cancer by stimulating MUC1 expression. Int J Mol Med 2017;40(2):293–302. DOI: 10.3892/ijmm.2017.3009
5. Wang F., Zhang Q., Zhang H. et al. MUC16 promotes EOC proliferation by regulating GLUT1 expression. J Cell Mol Med 2021;25(6):3031–40. DOI: 10.1111/jcmm.16345
6. Coelho R., Ricardo S., Amaral A.L. et al. Regulation of invasion and peritoneal dissemination of ovarian cancer by mesothelin manipulation. Oncogenesis 2020;9(6):61.
7. Rump A., Morikawa Y., Tanaka M. et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 2004;279(10):9190–8.
8. Albarracin C.T., Jafri J., Montag A.G. et al. Differential expression of MUC2 and MUC5AC mutin genes in primary ovarian and metastatic colonic carcinoma. Hum Pathol.2000;31(6):672–7. DOI: 10.1053/hupa.2000.6799
9. Hirabayashi K., Yasuda M., Kajiwara H. et al. Alterations in mucin expression in ovarian mucinous tumors: Immunohistochemical analysis of MUC2, MUC5AC, MUC6, and CD10 expression. Acta Histochem. Cytoc 2008;41(2):15–21. DOI: 10.1267/ahc.08008
10. Ohya A., Matoba H., Fujinaga Y., Nakayama J. Decreased gastric gland mucin-specific O-glycans are involved in the progression of ovarian primary mucinous tumours. Acta Histochem Cytoc 2021;54(4):115–22.
11. Rico S.D., Schmalfeldt B., Müller V. et al. MUC5AC expression is linked to mucinous/endometroid subtype, absence of nodal metastasis and mismatch repair deficiency in ovarian cancer. Pathol Res Pract 2021;224:153533. DOI: 10.1016/j.prp.2021.153533
12. Chauhan S.C., Vannatta K., Ebeling M.C. et al. Expression and functions of transmembrane mucin MUC13 in ovarian cancer. Cancer Res 2009;69(3):765–74.
13. Boivin M., Lane D., Piché A., Rancourt C. CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis. Gynecol Oncol 2009;115(3):407–13.
14. Matte I., Lane D., Boivin M. et al. MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression. BMC Cancer 2014;14(1):1–14.
15. Fass D., Thornton D.J. Mucin networks: Dynamic structural assemblies controlling mucus function. Curr Opin Struct Biol 2023;79:102524. DOI: 10.1016/j.sbi.2022.102524
16. Javitt G., Khmelnitsky L., Albert L. et al. Assembly mechanism of mucin and von Willebrand factor polymers. Cell 2020;183:717–29. DOI: 10.1016/j.cell.2020.09.021
17. Skrypek N., Duchêne B., Hebbar M. et al. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family. Oncogene 2013;32(13):1714–23. DOI: 10.1038/onc.2012.179
18. Ponnusamy M.P., Seshacharyulu P., Vaz A. et al. MUC4 stabilizes HER2 expression and maintains the cancer stem cell population in ovarian cancer cells. J Ovarian Res 2011;4(1):1–10. DOI: 10.1186/1757-2215-4-7
19. Beatson R.E., Taylor-Papadimitriou J., Burchell J.M. MUC1 immunotherapy. Immunotherapy 2010;2(3):305–27.
20. Tang C.K., Katsara M., Apostolopoulos V. Strategies used for MUC1 immunotherapy: Human clinical studies. Expet Rev Vaccine 2008;7(7):963–75. DOI: 10.1586/14760584.7.7.963
21. Liu N., Zhou C., Zhao J., Chen Y. Reversal of paclitaxel resistance in epithelial ovarian carcinoma cells by a MUC1 aptamer-let-7i chimera. Cancer Invest 2012;30(8):577–82. DOI: 10.3109/07357907.2012.707265
22. Dai F., Zhang Y., Zhu X. et al. The anti-chemoresistant effect and mechanism of MUC1 aptamer-miR-29b chimera in ovarian cancer. Gynecol Oncol 2013;131(2):451–9. DOI: 10.1016/j.ygyno.2013.07.112
23. Wu X., Kang Y., He Y. et al. Degradation of the surface mucus layer of mucinous ovarian cancer and its significance for the anti-cancer effect of Taxol. Chinese J Pract Gynecol Obstet 2008;7:526–8.
24. Danielczyk A., Stahn R., Faulstich D. et al. PankoMab: A potent new generation anti-tumour MUC1 antibody. Cancer Immunol Immunother 2006;55(11):1337–47.
25. Fiedler W., DeDosso S., Cresta S. et al. A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas. Eur J Cancer 2016;63:55–63. DOI: 10.1016/j.ejca.2016.05.003
26. Ledermann J.A., Zurawski B., Raspagliesi F. et al. Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: Results from a double-blind, placebo-controlled, randomized, phase II study. ESMO Open 2022;7(1):100311. DOI: 10.1016/j.esmoop.2021.100311
27. Gray H.J., Gargosky S.E. Progression-free survival in ovarian cancer patients in second remission with mucin-1 autologous dendritic cell therapy. J Clin Oncol 2014;32(15 Suppl):5504.
28. Mitchell P.L., Quinn M.A., Grant P.T. et al. A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer. J Immunother Cancer 2014;2:1–9. DOI: 10.1186/2051-1426-2-16
29. Berek J.S., Taylor P.T., Gordon A. et al. Randomized, placebocontrolled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 2004;22(17):3507–16. DOI: 10.1200/JCO.2004.09.016
30. Braly P., Nicodemus C.F., Chu C. et al. The Immune adjuvant properties of front-line carboplatin-paclitaxel: A randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer. J Immunother 2009;32(1):54–65.
31. Brewer M., Angioli R., Scambia G. et al. Front-line chemoimmunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study. Gynecol Oncol 2020;156(3):523–9. DOI: 10.1016/j.ygyno.2019.12.024
32. Secord A.A., Barroilhet L.M., Lim M.C. et al. FLORA-5/GOG3035: Frontline chemo-immunotherapy paclitaxel-carboplatinoregovomab [PCO] versus chemotherapy (paclitaxel-carboplatinplacebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC) – Phase III, double-blind, placebo-controlled, global, multinational study. J Clin Oncol 2022;40(16 Suppl):TPS5619.
33. Sabbatini P., Harter P., Scambia G. et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: A phase III trial of the AGO OVAR, COGI, GINECO, and GEICO-the MIMOSA study. J Clin Oncol 2013;31(12):1554. DOI: 10.1200/JCO.2012.46.4057
34. El Bairi K., Al Jarroudi O., Afqir S. Revisiting antibody-drug conjugates and their predictive biomarkers in platinum-resistant ovarian cancer. Semin Cancer Biol 2021;77:42–55. DOI: 10.1016/j.semcancer.2021.03.031
35. Liu J.F., Moore K.N., Birrer M.J. et al. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann Oncol 2016;27(11):2124–30. DOI: 10.1093/annonc/mdw401
36. Liu J., Burris H., Wang J.S. et al. An open-label phase I doseescalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer. Gynecol Oncol 2021;163(3):473–80. DOI: 10.1016/j.ygyno.2021.09.023
37. Crawford A., Haber L., Kelly M.P. et al. A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer. Sci Transl Med 2019;11(497):eaau7534.
38. Yeku O.O., Rao T.D., Laster I. et al. Bispecific T-cell engaging antibodies against MUC16 demonstrate efficacy against ovarian cancer in monotherapy and in combination with PD-1 and VEGF inhibition. Front Immunol 2021;12:663379. DOI: 10.3389/fimmu.2021.663379.
39. Chekmasova A.A., Rao T.D., Nikhamin Y. et al. Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clin Cancer Res 2010;16(14):3594–606. DOI: 10.1158/1078-0432.CCR-10-0192
40. Li T., Wang J. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice. BMC Cancer 2020;20:1–13. DOI: 10.1186/s12885-020-07180-x
Рецензия
Для цитирования:
Кедрова А.Г., Греян Т.А. Муцины как фактор канцерогенеза и потенциальная мишень терапии муцинозных опухолей яичников. Опухоли женской репродуктивной системы. 2024;20(4):127-132. https://doi.org/10.17650/1994-4098-2024-20-4-127-132
For citation:
Kedrova A.G., Greyan T.A. Mucins as a factor of carcinogenesis and a potential target for therapy of mucinous ovarian tumors. Tumors of female reproductive system. 2024;20(4):127-132. (In Russ.) https://doi.org/10.17650/1994-4098-2024-20-4-127-132
Просмотров:
55
Послать статью по эл. почте 